Global Ocular Gene Therapy 麻豆原创 Research Report 2024

Publication ID:

PB505246453

Publication Date:

May 30, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Ocular Gene Therapy market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Ocular Gene Therapy is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Ocular Gene Therapy is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Ocular Gene Therapy in Hospitals is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Ocular Gene Therapy include AbbVie, MeriaGTx, Regenxbio, GenSight Biologics, Astellas, Neurophth Therapeutics, Innostellar Biotherapeutics, Exegenesis Bio, Zhongyin Technology, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Ocular Gene Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ocular Gene Therapy.
The Ocular Gene Therapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Ocular Gene Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Ocular Gene Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
AbbVie
MeriaGTx
Regenxbio
GenSight Biologics
Astellas
Neurophth Therapeutics
Innostellar Biotherapeutics
Exegenesis Bio
Zhongyin Technology
Segment by Type
Gene Replacement Technology
Gene Editing Technology
Others
Segment by Application
Hospitals
Diagnostics Centers
Research Institutes
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Ocular Gene Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Ocular Gene Therapy 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Gene Replacement Technology
1.2.3 Gene Editing Technology
1.2.4 Others
1.3 麻豆原创 by Application
1.3.1 Global Ocular Gene Therapy 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Diagnostics Centers
1.3.4 Research Institutes
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Ocular Gene Therapy 麻豆原创 Perspective (2019-2030)
2.2 Global Ocular Gene Therapy Growth Trends by Region
2.2.1 Global Ocular Gene Therapy 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Ocular Gene Therapy Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Ocular Gene Therapy Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Ocular Gene Therapy 麻豆原创 Dynamics
2.3.1 Ocular Gene Therapy Industry Trends
2.3.2 Ocular Gene Therapy 麻豆原创 Drivers
2.3.3 Ocular Gene Therapy 麻豆原创 Challenges
2.3.4 Ocular Gene Therapy 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Ocular Gene Therapy Players by Revenue
3.1.1 Global Top Ocular Gene Therapy Players by Revenue (2019-2024)
3.1.2 Global Ocular Gene Therapy Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Ocular Gene Therapy 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Ocular Gene Therapy Revenue
3.4 Global Ocular Gene Therapy 麻豆原创 Concentration Ratio
3.4.1 Global Ocular Gene Therapy 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Ocular Gene Therapy Revenue in 2023
3.5 Global Key Players of Ocular Gene Therapy Head office and Area Served
3.6 Global Key Players of Ocular Gene Therapy, Product and Application
3.7 Global Key Players of Ocular Gene Therapy, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Ocular Gene Therapy Breakdown Data by Type
4.1 Global Ocular Gene Therapy Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Ocular Gene Therapy Forecasted 麻豆原创 Size by Type (2025-2030)
5 Ocular Gene Therapy Breakdown Data by Application
5.1 Global Ocular Gene Therapy Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Ocular Gene Therapy Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Ocular Gene Therapy 麻豆原创 Size (2019-2030)
6.2 North America Ocular Gene Therapy 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Ocular Gene Therapy 麻豆原创 Size by Country (2019-2024)
6.4 North America Ocular Gene Therapy 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Ocular Gene Therapy 麻豆原创 Size (2019-2030)
7.2 Europe Ocular Gene Therapy 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Ocular Gene Therapy 麻豆原创 Size by Country (2019-2024)
7.4 Europe Ocular Gene Therapy 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Ocular Gene Therapy 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Ocular Gene Therapy 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Ocular Gene Therapy 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Ocular Gene Therapy 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Ocular Gene Therapy 麻豆原创 Size (2019-2030)
9.2 Latin America Ocular Gene Therapy 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Ocular Gene Therapy 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Ocular Gene Therapy 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Ocular Gene Therapy 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Ocular Gene Therapy 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Ocular Gene Therapy 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Ocular Gene Therapy 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Details
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Ocular Gene Therapy Introduction
11.1.4 AbbVie Revenue in Ocular Gene Therapy Business (2019-2024)
11.1.5 AbbVie Recent Development
11.2 MeriaGTx
11.2.1 MeriaGTx Company Details
11.2.2 MeriaGTx Business Overview
11.2.3 MeriaGTx Ocular Gene Therapy Introduction
11.2.4 MeriaGTx Revenue in Ocular Gene Therapy Business (2019-2024)
11.2.5 MeriaGTx Recent Development
11.3 Regenxbio
11.3.1 Regenxbio Company Details
11.3.2 Regenxbio Business Overview
11.3.3 Regenxbio Ocular Gene Therapy Introduction
11.3.4 Regenxbio Revenue in Ocular Gene Therapy Business (2019-2024)
11.3.5 Regenxbio Recent Development
11.4 GenSight Biologics
11.4.1 GenSight Biologics Company Details
11.4.2 GenSight Biologics Business Overview
11.4.3 GenSight Biologics Ocular Gene Therapy Introduction
11.4.4 GenSight Biologics Revenue in Ocular Gene Therapy Business (2019-2024)
11.4.5 GenSight Biologics Recent Development
11.5 Astellas
11.5.1 Astellas Company Details
11.5.2 Astellas Business Overview
11.5.3 Astellas Ocular Gene Therapy Introduction
11.5.4 Astellas Revenue in Ocular Gene Therapy Business (2019-2024)
11.5.5 Astellas Recent Development
11.6 Neurophth Therapeutics
11.6.1 Neurophth Therapeutics Company Details
11.6.2 Neurophth Therapeutics Business Overview
11.6.3 Neurophth Therapeutics Ocular Gene Therapy Introduction
11.6.4 Neurophth Therapeutics Revenue in Ocular Gene Therapy Business (2019-2024)
11.6.5 Neurophth Therapeutics Recent Development
11.7 Innostellar Biotherapeutics
11.7.1 Innostellar Biotherapeutics Company Details
11.7.2 Innostellar Biotherapeutics Business Overview
11.7.3 Innostellar Biotherapeutics Ocular Gene Therapy Introduction
11.7.4 Innostellar Biotherapeutics Revenue in Ocular Gene Therapy Business (2019-2024)
11.7.5 Innostellar Biotherapeutics Recent Development
11.8 Exegenesis Bio
11.8.1 Exegenesis Bio Company Details
11.8.2 Exegenesis Bio Business Overview
11.8.3 Exegenesis Bio Ocular Gene Therapy Introduction
11.8.4 Exegenesis Bio Revenue in Ocular Gene Therapy Business (2019-2024)
11.8.5 Exegenesis Bio Recent Development
11.9 Zhongyin Technology
11.9.1 Zhongyin Technology Company Details
11.9.2 Zhongyin Technology Business Overview
11.9.3 Zhongyin Technology Ocular Gene Therapy Introduction
11.9.4 Zhongyin Technology Revenue in Ocular Gene Therapy Business (2019-2024)
11.9.5 Zhongyin Technology Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

AbbVie
MeriaGTx
Regenxbio
GenSight Biologics
Astellas
Neurophth Therapeutics
Innostellar Biotherapeutics
Exegenesis Bio
Zhongyin Technology

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.